BMY Bristol-Myers Squibb Company Common Stock
$67,40
Kurs · Aug 25, 2026
Fundamentaldaten per Jul 30, 2026
52W-Spanne
$43–$69
95% of range
Analystenbewertung
HOLD
35 analysts
Kursziel
$66
P/E (TTM)
15.6
ROE
40.5%
Nettogewinnmarge
14.6%
Über Bristol-Myers Squibb Company Common Stock Unternehmensübersicht von Wikipedia
Bristol-Myers Squibb, allgemein abgekürzt BMS, ist ein Pharmazieunternehmen, das 1989 durch die Fusion der Unternehmen Bristol-Myers Company und Squibb Corporation entstand. Das Unternehmen hat seinen Hauptsitz in New York. 2022 erwirtschaftete BMS einen weltweiten Jahresumsatz von 43,8 Mrd. USD.
Mehr lesen
Bristol-Myers Squibb, allgemein abgekürzt BMS, ist ein Pharmazieunternehmen, das 1989 durch die Fusion der Unternehmen Bristol-Myers Company und Squibb Corporation entstand. Das Unternehmen hat seinen Hauptsitz in New York. 2022 erwirtschaftete BMS einen weltweiten Jahresumsatz von 43,8 Mrd. USD.
BMS wird auf der Liste Forbes Global 2000 geführt.
Geschichte
E. R. Squibb wurde 1858 von Edward Robinson Squibb (1819–1900) in Brooklyn gegründet. Das Unternehmen war bekannt für hohe Qualitätsstandards und zeitweise veröffentlichten sie auch eine Alternative zur US Pharmacopeia (Squibb's Ephemeris of Materia Medica). Im Sezessionskrieg waren sie ein Hauptlieferant von Pharmaka für die Nordstaatenarmee. 1938 eröffnete Squibb das Squibb Institute for Medical Research in New Brunswick (New Jersey) als Forschungslabor. Dieses erhielt 1955 den Lasker~DeBakey Clinical Medical Research Award. 1944 eröffneten sie die größte Penicillin-Fabrik in den USA in New Brunswick.
Bristol-Myers entstand 1898 aus der von William McLaren Bristol (1860–1935) und John Ripley Myers (1864–1899) in Clinton (New Jersey) 1887 übernommenen Clinton Pharmaceutical Company. Zunächst hatten sie Erfolg mit einem Abführmittel (Sal Hepatica, den Mineralwässern Böhmens nachempfunden) und einer Zahnpasta. Ab 1943 begannen sie Penicillin für die US-Armee zu produzieren (in East Syracuse, wo die Bristol Laboratories entstanden) und setzten ihr Engagement für Antibiotika nach dem Zweiten Weltkrieg fort. Dabei standen sie in Konkurrenz zu Squibb. 1989 fusionierten beide Unternehmen.
2019 erfolgte eine Übernahme (Merger) von Celgene durch Bristol-Myers Squibb für 74 Milliarden US-Dollar. Aufgrund von Auflagen musste das Psoriasis-Produkt Otezla (Apremilast) an Amgen verkauft werden.
BMS erwarb 2022 Turning Point Therapeutics für 4,1 Milliarden Dollar und damit den noch in klinischer Entwicklung befindlichen Wirkstoff Repotrectinib des Präzisionsonkologie-Unternehmens. Repotrectinib (TPX-0005) ist ein Tyrosinkinase-Inhibitor (TKI) der nächsten Generation, der bei NSCLC und anderen fortgeschrittenen soliden Tumoren eingesetzt werden soll.
Produkte
BMS-Produktionsstätten stellen Medikamente und Gesundheitsprodukte für verschiedene Therapiebereiche her. Zu dem Unternehmen BMS gehörte von 1967 bis zum Verkauf an Reckitt Benckiser im Jahr 2017 auch das Tochterunternehmen Mead Johnson, das Ernährungsprodukte, wie Enfamil baby formulas, und Vitaminzusätze für Kinder, wie Tri-Vi-Sol, herstellt. Ebenfalls zu BMS gehörten die Unternehmen Medical Imaging (bis 2007) sowie ConvaTec Stoma- und Wundversorgung (bis 2008). BMS hält außerdem Anteile an ImClone, einem Biotech-Unternehmen. Ursprünglich wollte BMS das Unternehmen ImClone komplett übernehmen. Im August 2008 sah sich BMS in Deutschland mit der Markteinführung von Clopidogrelbesilat der Generikahersteller Ratiopharm und Hexal konfrontiert, das Iscover als Arzneimittel mit dem weltweit zweitgrößten Umsatz durch deutlich niedrigere Preise Konkurrenz machte.
Unter anderem vertreibt BMS folgende patentierte Medikamente:
Immunologie
Orencia (Abatacept)
Nulojix (Belatacept)
Zeposia (Ozanimod)
Sotyktu (Deucravacitinib)
Herz/Kreislauf
Eliquis (Apixaban)
Camzyos (Mavacamten)
Onkologie
Inrebic (Fedratnib)
Sprycel (Dasatinib)
Yervoy (Ipilimumab)
Opdivo (Nivolumab)
HIV
Reyataz (Atazanavir)
Sustiva (Efavirenz)
Videx (Didanosin)
Zerit (Stavudin)
Hepatitis B
Baraclude (Entecavir)
Kritik
Der US-Bundesrichter Theodore Chuang entschied Anfang Januar 2019, dass sich Bristol-Myers Squibb, die Johns-Hopkins-Universität und die Rockefeller-Stiftung gemeinsam für den Vorwurf von Menschenversuchen mit Syphilis in Guatemala in den 1940er- und 1950er-Jahren verantworten müssten. Demnach wären hunderte Soldaten, psychisch Kranke, Prostituierte und verurteilte Straftäter mit Syphilis infiziert worden, um die Wirksamkeit von Penicillin dagegen zu testen. 2010 wandte sich Präsident Obama mit Worten der Entschuldigung an die Opfer. Im Jahr 2015 hatten 774 Opfer und Opferangehörige Klage eingereicht. Sie versichern, die Versuche seien ohne Wissen oder Zustimmung der Betroffenen erfolgt. Nach Chuang fordern die Kläger insgesamt eine Milliarde Dollar Entschädigung.
== Quellen ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
BMY Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$67.40
Marktkapitalisierung
—
P/E (TTM)
15.6
EPS (TTM)
$3.46
Umsatz (TTM)
$48.19B
Dividendenrendite
—
ROE
40.5%
Verschuldungsgrad
2.5
52W-Spanne
$43 – $69
BMY Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$48.19B
2019-12-31
→
2025-12-31
EPS
$3.46
2019-12-31
→
2025-12-31
Freier Cashflow
$12.85B
2019-12-31
→
2025-12-31
Margen
14.6%
2019-12-31
→
2020-12-31
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
BMY
Peer-Median
P/E (TTM)
15.6
32.1
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
BMY
Peer-Median
Net Profit Margin (Nettogewinnmarge)
14.6%
13.0%
ROA
7.7%
6.4%
ROE
40.5%
15.1%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
BMY
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
2.5
—
Current Ratio (Liquiditätsgrad)
1.3
1.6
Quick Ratio
0.8
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
BMY
Peer-Median
Revenue YoY (Umsatz YoY)
-0.22%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
1.5%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
2.5%
—
EPS YoY (EPS VjV)
30.9%
—
Net Income YoY (Nettogewinn YoY)
26.8%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
BMY
Peer-Median
Payout Ratio (Ausschüttungsquote)
71.5%
—
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Dividendenrendite
—
Ausschüttungsquote
71.5%
5J Div CAGR
—
| Ex-Datum | Betrag |
|---|---|
| 2. Juli 2026 | $0,6300 |
| 2. April 2026 | $0,6300 |
| 2. Januar 2026 | $0,6300 |
| 3. Oktober 2025 | $0,6200 |
| 3. Juli 2025 | $0,6200 |
| 4. April 2025 | $0,6200 |
| 3. Januar 2025 | $0,6200 |
| 4. Oktober 2024 | $0,6000 |
| 5. Juli 2024 | $0,6000 |
| 4. April 2024 | $0,6000 |
| 4. Januar 2024 | $0,6000 |
| 5. Oktober 2023 | $0,5700 |
| 6. Juli 2023 | $0,5700 |
| 6. April 2023 | $0,5700 |
| 5. Januar 2023 | $0,5700 |
| 6. Oktober 2022 | $0,5400 |
| 30. Juni 2022 | $0,5400 |
| 31. März 2022 | $0,5400 |
| 6. Januar 2022 | $0,5400 |
| 30. September 2021 | $0,4900 |
BMY Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
35 Analysten
- Starker Kauf 6 17,1%
- Kauf 8 22,9%
- Halten 19 54,3%
- Verkauf 2 5,7%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
24 Analysten · 2026-08-24
Median
$68.00
Jetzt
$67.40
Tief
$40.00
Hoch
$80.00
Median-Ziel
$68.00
+0,9%
Mittelwert-Ziel
$66.21
-1,8%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.25%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $2.04 | $1.60 | 0.44% |
| 31. März 2026 | $1.58 | $1.43 | 0.15% |
| 31. Dezember 2025 | $1.26 | $1.13 | 0.13% |
| 30. September 2025 | $1.63 | $1.52 | 0.11% |
| 30. Juni 2025 | $1.46 | $1.08 | 0.38% |
| 31. März 2025 | $1.80 | $1.51 | 0.29% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
Bilanz 31
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
Cashflow 19
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
Rentabilität 6
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
Wachstumsraten 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 6
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
Bilanz 29
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
Cashflow 19
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
Liquidität & Solvenz 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
Bewertung (TTM) 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Nettoergebnis | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| Verwässerte EPS | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| Liquiditätsgrad | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
- Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 2.785 Einreicher · $58.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 159 (-159 vs. Vorquartal) | 154 (+18 vs. Vorquartal) | 1.006 (-29 vs. Vorquartal) | 987 (+89 vs. Vorquartal) | +55.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7.682.927.263 | 133.337.856 | 13,22% | Aktien |
| STATE STREET CORP | $5.900.803.123 | 102.408.940 | 10,15% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.894.809.793 | 67.594.755 | 6,70% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $2.858.273.235 | 49.750.183 | 4,92% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.700.823.125 | 46.873.015 | 4,65% | Aktien |
| NORGES BANK | $2.124.256.834 | 36.866.658 | 3,66% | Aktien |
| PRIMECAP MANAGEMENT CO/CA/ | $1.436.115.120 | 24.923.900 | 2,47% | Aktien |
| AMERIPRISE FINANCIAL INC | $1.308.030.705 | 22.705.049 | 2,25% | Aktien |
| Independent Franchise Partners LLP | $1.255.703.498 | 21.792.841 | 2,16% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $938.463.230 | 16.287.109 | 1,61% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $660.776.941 | 11.467.840 | 1,14% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $585.933.423 | 10.168.924 | 1,01% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $581.119.768 | 10.085.383 | 1,00% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494.716.447 | 8.585.846 | 0,85% | Aktien |
| BlackRock, Inc. | $492.399.085 | 8.545.628 | 0,85% | Aktien |
| FMR LLC | $451.250.223 | 7.831.486 | 0,78% | Aktien |
| TWO SIGMA ADVISERS, LP | $446.094.588 | 8.270.200 | 0,77% | Aktien |
| Robeco Institutional Asset Management B.V. | $417.435.581 | 7.244.630 | 0,72% | Aktien |
| GOLDMAN SACHS GROUP INC | $392.167.333 | 6.806.097 | 0,67% | Aktien |
| FIRST TRUST ADVISORS LP | $344.672.508 | 5.981.822 | 0,59% | Aktien |
| Capital International Investors | $340.767.005 | 5.913.752 | 0,59% | Aktien |
| Swiss National Bank | $331.822.056 | 5.758.800 | 0,57% | Aktien |
| VAN ECK ASSOCIATES CORP | $325.076.944 | 5.641.738 | 0,56% | Aktien |
| National Pension Service | $321.412.139 | 5.578.135 | 0,55% | Aktien |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319.229.612 | 5.540.268 | 0,55% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $316.480.270 | 5.492.542 | 0,54% | Aktien |
| Legal & General Group Plc | $315.258.552 | 5.471.339 | 0,54% | Aktien |
| M&G PLC | $306.949.282 | 5.292.229 | 0,53% | Aktien |
| NORDEA INVESTMENT MANAGEMENT AB | $300.773.017 | 5.232.200 | 0,52% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $293.408.012 | 5.092.121 | 0,50% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $288.555.718 | 4.757.720 | 0,50% | Aktien |
| Vanguard Global Advisers, LLC | $270.856.466 | 4.700.737 | 0,47% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $266.201.519 | 4.619.950 | 0,46% | Aktien |
| California Public Employees Retirement System | $263.375.546 | 4.570.905 | 0,45% | Aktien |
| BANK OF AMERICA CORP /DE/ | $263.115.723 | 4.566.396 | 0,45% | Aktien |
| VANGUARD GROUP INC | $247.970.649 | 4.597.157 | 0,43% | Aktien |
| Caisse de depot et placement du Quebec | $243.646.343 | 4.228.503 | 0,42% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $241.222.903 | 4.186.444 | 0,42% | Aktien |
| JANE STREET GROUP, LLC | $224.896.622 | 3.903.100 | 0,39% | Kaufoption |
| WELLINGTON MANAGEMENT GROUP LLP | $214.546.630 | 3.723.475 | 0,37% | Aktien |
| Employees Provident Fund Board | $209.755.987 | 3.640.333 | 0,36% | Aktien |
| CITADEL ADVISORS LLC | $194.502.072 | 3.375.600 | 0,33% | Verkaufsoption |
| RHUMBLINE ADVISERS | $192.874.042 | 3.347.347 | 0,33% | Aktien |
| LPL Financial LLC | $188.151.217 | 3.265.381 | 0,32% | Aktien |
| BARCLAYS PLC | $186.163.076 | 3.230.876 | 0,32% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $185.255.963 | 3.215.133 | 0,32% | Aktien |
| UBS Group AG | $180.243.196 | 3.128.136 | 0,31% | Aktien |
| Qube Research & Technologies Ltd | $178.273.860 | 3.093.958 | 0,31% | Aktien |
| Artemis Investment Management LLP | $175.941.518 | 3.053.480 | 0,30% | Aktien |
| SEB Asset Management AB | $165.520.833 | 2.872.632 | 0,28% | Aktien |
| Ensign Peak Advisors, Inc | $165.119.502 | 2.865.663 | 0,28% | Aktien |
| CITADEL ADVISORS LLC | $157.769.322 | 2.738.100 | 0,27% | Kaufoption |
| JANE STREET GROUP, LLC | $152.525.902 | 2.647.100 | 0,26% | Verkaufsoption |
| NATIXIS | $145.152.674 | 2.519.137 | 0,25% | Aktien |
| AustralianSuper Pty Ltd | $140.209.857 | 2.433.354 | 0,24% | Aktien |
| Mirae Asset Global Investments Co., Ltd. | $138.044.440 | 2.395.773 | 0,24% | Aktien |
| Bank of New York Mellon Corp | $136.334.163 | 2.366.091 | 0,23% | Aktien |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132.803.901 | 2.304.823 | 0,23% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $132.622.456 | 2.301.674 | 0,23% | Aktien |
| Capital World Investors | $129.313.224 | 2.244.242 | 0,22% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $129.300.432 | 2.244.020 | 0,22% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125.419.207 | 2.176.661 | 0,22% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $123.353.032 | 2.140.802 | 0,21% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122.879.893 | 2.132.591 | 0,21% | Aktien |
| PFA Pension, Forsikringsaktieselskab | $121.829.832 | 2.114.367 | 0,21% | Aktien |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120.528.714 | 2.234.496 | 0,21% | Aktien |
| MACKENZIE FINANCIAL CORP | $118.944.044 | 2.064.284 | 0,20% | Aktien |
| Pictet Asset Management Holding SA | $116.783.155 | 2.026.687 | 0,20% | Aktien |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116.161.574 | 2.015.994 | 0,20% | Aktien |
| TD Asset Management Inc | $115.669.154 | 2.007.448 | 0,20% | Aktien |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115.240.000 | 2.000.000 | 0,20% | Kaufoption |
| MACQUARIE GROUP LTD | $111.978.478 | 1.943.396 | 0,19% | Aktien |
| Vinva Investment Management Ltd | $109.557.913 | 1.870.866 | 0,19% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $108.509.833 | 1.883.218 | 0,19% | Aktien |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106.751.521 | 1.760.124 | 0,18% | Aktien |
| LMR Partners LLP | $106.066.896 | 1.840.800 | 0,18% | Verkaufsoption |
| AVIVA PLC | $103.620.639 | 1.798.345 | 0,18% | Aktien |
| PRUDENTIAL FINANCIAL INC | $103.202.606 | 1.791.090 | 0,18% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102.378.000 | 1.776.782 | 0,18% | Aktien |
| STOREBRAND ASSET MANAGEMENT AS | $101.037.131 | 1.753.508 | 0,17% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100.790.172 | 1.749.222 | 0,17% | Aktien |
| BANK OF NOVA SCOTIA | $99.453.647 | 1.726.026 | 0,17% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98.875.920 | 1.716.000 | 0,17% | Aktien |
| KLP KAPITALFORVALTNING AS | $94.673.002 | 1.643.058 | 0,16% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90.576.678 | 1.567.009 | 0,16% | Aktien |
| BANK OF MONTREAL /CAN/ | $89.684.378 | 1.556.480 | 0,15% | Aktien |
| Douglas Lane & Associates, LLC | $89.667.305 | 1.556.184 | 0,15% | Aktien |
| PNC Financial Services Group, Inc. | $89.112.096 | 1.546.548 | 0,15% | Aktien |
| Walleye Trading LLC | $88.014.550 | 1.527.500 | 0,15% | Kaufoption |
| Korea Investment CORP | $86.518.389 | 1.501.534 | 0,15% | Aktien |
| APG Asset Management N.V. | $85.242.422 | 1.691.386 | 0,15% | Aktien |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85.175.958 | 1.478.236 | 0,15% | Aktien |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84.205.059 | 1.764.695 | 0,14% | Aktien |
| Mariner, LLC | $83.309.670 | 1.445.809 | 0,14% | Aktien |
| Retirement Systems of Alabama | $80.928.212 | 1.404.516 | 0,14% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $80.695.542 | 1.400.478 | 0,14% | Aktien |
| Nuveen Asset Management, LLC | $76.733.142 | 1.356.668 | 0,13% | Aktien |
| CWM, LLC | $76.220.909 | 1.256.734 | 0,13% | Aktien |
| Eurizon Capital SGR S.p.A. | $70.986.984 | 1.230.296 | 0,12% | Aktien |
| Aberdeen Group plc | $70.798.674 | 1.228.717 | 0,12% | Aktien |
Unternehmensinsider 102 Insider · 65 Führungskräfte · 37 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 13. Juni 2025 G | 125.439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 8. September 2006 F | 571.673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 1. April 2026 S | 159.248 | 0 | 3 | $-4.500.496 |
| Jean-Marc Huet | EVP & CFO | 30. April 2009 P | 25.000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 9. Mai 2025 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 10. März 2025 A | 4.711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 2. März 2004 A | 178.889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 10. September 2003 A | 60.000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 1. August 2026 M | 24.997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 1. August 2026 M | 13.649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 3. Juni 2026 F | 12.081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 1. Juli 2025 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 1. Mai 2025 J | 12.439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 25. April 2025 P | 83.513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1. April 2025 M | 13.797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 10. März 2025 A | 14.967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 10. März 2025 A | 5.196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 10. März 2025 A | 16.102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 10. März 2025 A | 15.839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 10. März 2025 A | 364.296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 10. März 2024 M | 432.266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 24. August 2023 S | 27.868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 1. Juli 2023 M | 3.453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 3. Mai 2023 S | 47.751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 2. Mai 2023 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 1. April 2023 M | 34.734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 14. März 2022 S | 16.704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 24. November 2021 S | 63.536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 30. Juli 2021 S | 13.777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 3. Juni 2021 M | 9.485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 10. Mai 2021 S | 31.956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 10. März 2020 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 10. März 2020 M | 70.946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 10. März 2020 M | 137.534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 2. Oktober 2019 M | 6.214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 3. April 2019 M | 22.223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 1. August 2018 M | 49.424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 6. September 2017 S | 46.297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 3. September 2017 M | 37.974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 10. März 2017 A | 20.138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 10. März 2017 M | 321.906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 13. März 2015 S | 31.015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 1. Juli 2014 M | 94.374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 10. März 2014 A | 4.174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 3. Juni 2013 M | 148.221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 31. Mai 2013 S | 173.375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 6. März 2012 M | 142.142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 1. Oktober 2011 M | 43.689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 14. Juni 2011 M | 7.578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 13. Mai 2011 M | 203.170 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 11 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 Einreichungen | 16. Juli 2020 | — | Erste Einreichung | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 27. Februar 2019 | — | Erste Einreichung | Passive Anlage | SEC |
| S.S. OR ×3 Einreichungen | 23. Dezember 2009 | — | Erste Einreichung | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 25. November 2009 | — | Erste Einreichung | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 Einreichungen | 27. Februar 2009 | — | Erste Einreichung | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 Einreichungen | 8. Oktober 2008 | — | Erste Einreichung | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 Einreichungen | 6. Juni 2003 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 16. April 2003 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 3. Februar 2003 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 6. März 2002 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 6. Februar 2002 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 296 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 6,29% | 39.590 NS | 30. Juni 2026 | N-PORT |
| RDIV · Invesco Exchange-Traded Fund Trust … | 5,25% | 1.134.150 SH | 21. August 2026 | Täglich |
| ROPE · EA Series Trust | 4,97% | 7.379 NS | 29. Mai 2026 | N-PORT |
| IHE · iShares Trust | 4,65% | 1.223.984 SH | 21. August 2026 | Täglich |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4,10% | 44.768 NS | 30. April 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,50% | 6.427 NS | 30. April 2026 | N-PORT |
| FDL · First Trust Exchange-Traded Fund | 3,43% | 4.337.329 NS | 30. Juni 2026 | N-PORT |
| CANC · Tema ETF Trust | 3,30% | 101.680 NS | 31. Mai 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,21% | 2.332 NS | 30. April 2026 | N-PORT |
| AGNG · Global X Funds | 2,98% | 42.594 NS | 31. Mai 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2,93% | 48.641.121 NS | 31. Mai 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,78% | 224.546 SH | 21. August 2026 | Täglich |
| ABFL · Abacus FCF ETF Trust | 2,76% | 226.688 NS | 30. April 2026 | N-PORT |
| HDV · iShares Trust | 2,62% | 6.134.190 SH | 21. August 2026 | Täglich |
| ACEP · EA Series Trust | 2,52% | 44.211 NS | 29. Mai 2026 | N-PORT |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 234.394 NS | 31. Mai 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 210.030 NS | 31. Mai 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,45% | 148.728 NS | 31. Mai 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,18% | 1.612 NS | 30. April 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,10% | 38.747 SH | 21. August 2026 | Täglich |
| HRTS · Tema ETF Trust | 2,09% | 18.939 NS | 31. Mai 2026 | N-PORT |
| FDIV · EA Series Trust | 2,07% | 24.896 NS | 30. April 2026 | N-PORT |
| IYH · iShares Trust | 2,06% | 1.218.183 SH | 21. August 2026 | Täglich |
| SPHD · Invesco Exchange-Traded Fund Trust … | 2,06% | 1.086.835 SH | 21. August 2026 | Täglich |
| GCOW · Pacer Funds Trust | 2,03% | 1.123.894 NS | 30. April 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 2,03% | 6.082.360 NS | 30. April 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 2,03% | 15.628 NS | 30. April 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,02% | 30.055 NS | 30. April 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,99% | 938.456 NS | 30. April 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 1,98% | 1.422 NS | 30. April 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,93% | 31.120 SH | 21. August 2026 | Täglich |
| PEY · Invesco Exchange-Traded Fund Trust | 1,83% | 327.924 SH | 21. August 2026 | Täglich |
| SDOG · ALPS ETF Trust | 1,83% | 441.820 NS | 31. Mai 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 1,82% | 27.812 NS | 31. Mai 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1,78% | 40.606 NS | 30. April 2026 | N-PORT |
| FLOW · Global X Funds | 1,78% | 8.912 NS | 31. Mai 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 1,73% | 6.137.665 SH | 19. August 2026 | Täglich |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,70% | 213.437 SH | 21. August 2026 | Täglich |
| RXL · ProShares Trust | 1,68% | 21.228 NS | 31. Mai 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,66% | 26.358 NS | 31. Mai 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 1,65% | 12.671 NS | 30. April 2026 | N-PORT |
| IXJ · iShares Trust | 1,61% | 1.073.117 SH | 21. August 2026 | Täglich |
| NULV · Nushares ETF Trust | 1,57% | 539.514 NS | 30. April 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,54% | 13.556 NS | 30. April 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,54% | 11.473 NS | 30. April 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,47% | 415.736 SH | 21. August 2026 | Täglich |
| COWG · Pacer Funds Trust | 1,47% | 526.151 NS | 30. April 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,46% | 68.134 NS | 30. April 2026 | N-PORT |
| TMFE · RBB Fund, Inc. | 1,45% | 21.473 NS | 31. Mai 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,43% | 64.178 NS | 30. April 2026 | N-PORT |